John Griffiths  2007 – 2016

Retired; Emeritus Group Leader CRUK CI.
Magnetic Resonance Imaging and spectroscopy of cancer. Our Group developed and applied Magnetic Resonance Spectroscopy (MRS) and Imaging (MRI) methods that will aid in the understanding and therapy of cancer.

 

David Neal  2007 – 2014

Professor of Surgical Oncology, Nuffield Department of Surgical Sciences, Oxford.
At the CRUK CI, his research focused on the molecular pathology of prostate cancer, particularly on how the androgen receptor interacts with the prostate cancer genome in order to identify potential biological targets and to stratify risk.

 

Gillian Murphy 2007 – 2013

Retired; Emeritus Group Leader CRUK CI.
The Murphy Group studied cell surface proteinases that modulate both the extracellular matrix and the activities of key cytokines and growth factors and have generated information on their structure-function relationships that are key to the understanding of their role in biology and pathology and the design of novel therapeutic approaches to cancer.

 

Adele Murrell 2007 – 2013

Department of Biology & Biochemistry, Centre for Regenerative Medicine, Bath.
Higher order chromatin structure and epigenetic modifications to DNA and histones shape the genome within the nucleus. She is now investigating how tumorigenesis and metastasis disrupt genome organisation and how this leads to the aberrant expression of several genes related to cancer cell survival.

 

John Stingl 2008 – 2015

Associate Director, STEMCELL Technologies, Vancouver, Canada.
While at CRUK CI, the Stingl group  focussed on identifying and characterising the cells that make up normal mammary epithelium and how they relate to those present in the different types of human breast tumours.  They were particularly interested in determining the cells of origin of the different types of breast cancer.

 

David Tuveson 2007 – 2012

Director of the Cancer Therapeutics Initiative at Cold Spring Harbor Laboratory, USA.
While at CRUK CI he worked to develop preclinical and clinical therapeutic strategies for pancreatic cancer. In Cambridge, his lab identified a variety of parameters that limit therapeutic efficacy in pancreatic cancer, including poor drug delivery and survival factors in the microenvironment. These findings are currently being evaluated in the clinic.

 

Fiona Watt 2007 – 2012

Director of the Centre for Stem Cells and Regenerative Medicine, King’s College London.
From 2006 to 2012 she was Deputy Director of the CRUK CI and Deputy Director of the Wellcome Trust Centre for Stem Cell Research, University of Cambridge. Her interest is in the role of stem cells in adult tissue maintenance. For many of her studies she used mammalian epidermis as a model system, both in the context of genetically modified mice and epidermal reconstitution in culture.